The FDA has given Elanco Animal Health approval of Imrestor™ – the first product of its kind for the dairy industry. Imrestor is only available from veterinary prescription for the reduction in the incidence of clinical mastitis in the first 30 days of lactation in periparturient dairy cows and periparturient replacement dairy heifers. The protein helps support the natural function of a dairy cow’s immune system when she is most vulnerable to mastitis.
“Imrestor is an innovative new approach for reducing clinical mastitis by proactively helping to restore the function of a cow’s immune system,” explained Paul Rapnicki, DVM, MBA, Associate Technical Advisor, Elanco Animal Health.
“We know that even the best producers need a little help protecting their dairy herds. Imrestor is a proactive approach that can help keep cows healthy and help reduce the frustration, financial strain and stress associated with treating mastitis,” added Rapnicki.
The launch of Imrestor is aligned with Elanco’s eight-point antibiotic stewardship plan that ensures the responsible use of antibiotics, reduces shared-class antibiotic use and replaces antibiotics with alternatives. The plan was outlined by Elanco President Jeff Simmons at a White House antibiotic stewardship forum last year.
Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – thus helping to protect the cow against mastitis when she needs it most. Imrestor does not require a meat or milk withdrawal period and will be available for purchase in 10, 50, and 100 dose pack sizes. Dairy producers are encouraged to contact their veterinarian to discuss incorporating Imrestor into their herd health program.